We are a techbio AI company helping pharma companies design vaccines and immunotherapies. We model MHC binding to peptides, and with generative AI, we generate candidates of the antigens. Our previous project was recognized by the Polish Health Ministry and deployed in a program where our software processed more than 50% of all PCR test results to distinguish more transmissible strains. We spent the last 18 months refining the technology and assembling a team of 12 scientists, AI engineers and PhDs. We also have closed a €1.5M pre-seed round from VCs in our field, further helping us to grow.